Industry News
Biotechnology Industry News

Pfizer has found a new home for an…
Pfizer has found a new home for an antibody-drug conjugate it acquired in its $43 billion Seagen buyout and dropped earlier this year.
AbbVie released positive phase 3…
AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates and progression-free survival in patients with relapsed/refractory multiple myeloma.
GSK is handing over $110 million…
GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a first-in-class oncology candidate.
Ultragenyx had been flying high…
Ultragenyx had been flying high after its recent FDA approval for Genglycos—but the company has been brought back down to earth with a damaging phase 3 flop.
H1 is transforming clinical…
H1 is transforming clinical development with connected intelligence that improves study design, accelerates execution, and reduces cost and patient burden
Teva Pharmaceutical’s dreams of a…
Teva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s anti-interleukin-15 antibody scored a midstage win in celiac disease.
The SEC and the FDA have signed a…
The SEC and the FDA have signed a three-year agreement to step up cooperation and information-sharing capabilities aiming to improve each organization’s regulatory and enforcement missions.
TCR-T specialist TScan…
TCR-T specialist TScan Therapeutics will reduce its workforce by 75% following the pause of its hematological and autoimmune programs.
Novartis has struck a deal worth…
Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and GSK on the list of drugmakers to pay to access the technology this year.
The overwhelming demand for GLP-1…
The overwhelming demand for GLP-1 weight loss drugs has reshaped the drug market, empowering consumers to take charge of their own health and removing barriers between their wallets and their medicine cabinets.
The announcement from Merck &…
The announcement from Merck & Co. and Moderna last month that their mRNA cancer vaccine had successfully lengthened patient survival in a phase 3 study affirmed the two companies' years of hard work and reignited
Roche is paying oncology-focused…
Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases.
About a year after halving its…
About a year after halving its staff in a clinical push, Arsenal Biosciences is now making a hard pivot that involves laying off most of its employees and seeking out new homes for its assets.
A phase 2b lupus trial of…
A phase 2b lupus trial of Alumis’ envudeucitinib has missed its primary and secondary endpoints. But the biotech is still moving the TYK2 inhibitor into phase 3 in the autoimmune disease, pointing to evidence of
GSK has linked its mRNA seasonal…
GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a phase 2 trial, emboldening the company to start a pivotal study this month.
Three deaths have forced Novartis…
Three deaths have forced Novartis to pause development of its CD19 CAR-T candidate in autoimmune diseases, just as Bristol Myers Squibb has halted a similar program due to immune-related adverse events, Fierce has learned.
As AstraZeneca appears to close…
As AstraZeneca appears to close the book on a combo approach following the phase 3 failure of its Ionis-partnered Wainua, several analysts contend it’s too early to count out Alnylam’s silencing drugs in ATTR-CM patients
The 2026 IPO streak continues as…
The 2026 IPO streak continues as Electra Therapeutics has filed to go public to support its immunology and cancer pipeline.
AstraZeneca’s oral relaxin…
AstraZeneca’s oral relaxin agonist delivered encouraging phase 2b results in chronic heart failure, improving measures of cardiac function across two patient groups.
Eli Lilly has struck a deal to…
Eli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to treat disease through the selective degradation of pathogenic autoantibodies.

